Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics announces its upcoming virtual presentation at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 10:00 a.m. ET. Investors can access the live webcast through the Investors section of Clarus’ website, with an archived version available for 90 days post-event. Clarus focuses on developing androgen and metabolic therapies, with its first product, JATENZO® (testosterone undecanoate). For more details, visit ClarusTherapeutics.com.

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer 32nd Annual Healthcare Conference, Tuesday, March 15, 2022, 10:00 a.m. ET.

The presentation will be webcast live and can be accessed through the Investors section of Clarus’ website at Investors.ClarusTherapeutics.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.

About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO^® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

JATENZO^® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Contact:
Kara Stancell
Vice President, Investor Relations & Corporate Communications
kstancell@clarustherapeutics.com
(847) 562-4300 x 206

 

FAQ

When is Clarus Therapeutics presenting at the Oppenheimer Annual Healthcare Conference?

Clarus Therapeutics is presenting virtually on March 15, 2022, at 10:00 a.m. ET.

How can I access the Clarus Therapeutics presentation?

The presentation can be accessed live through the Investors section of Clarus' website.

What is the focus of Clarus Therapeutics?

Clarus Therapeutics develops androgen and metabolic therapies for men and women.

What is JATENZO, and who developed it?

JATENZO® is a testosterone undecanoate product developed by Clarus Therapeutics.

What is the stock symbol for Clarus Therapeutics?

The stock symbols for Clarus Therapeutics are CRXT and CRXTW.